Circulating hyaluronan and hyaluronidase are increased in diabetic rats
Dear Sir, Hyaluronan (hyaluronic acid) is a highly charged high-molecular-mass polyanion of repeating disaccharide units, found at its most in the extracellular matrix of loose connective tissue. Hyaluronan is implicated in various physiological functions including water and protein homeostasis, cell proliferation, cell locomotion and migration. Serum hyaluronan was found to be a marker of several diseases (hepatitis, primary bilary cirrhosis, rheumatoid arthritis, tumours and other diseases affecting connective tissue) [1] . Previous investigations have shown that patients with Type I (insulin-dependent) diabetes mellitus present a relative and absolute increase in hyaluronan in normal tunica media of arteries compared with non-diabetic subjects [2] . The aim of this study was to determine whether circulating hyaluronan was influenced by Type I diabetes in rats. With this information, one explanation for the enhanced deposition of hyaluronan in the tunica-media of diabetic patients could be provided.
To induce diabetes, a single injection of streptozocin (streptozocin crystallized, Boehringer, Mannheim, Germany; 45 mg/ Kg body weight) dissolved in normal saline with sodium citrate (0.02 mol/l, pH 4.5) was carried out through the exposed jugular vein. Control rats received an equivalent volume of the dissolving buffer alone. A group of diabetic rats received (once daily between 1700 and 1800 hours during 6 weeks) a subcutaneous injection of a fixed dose (6 U/rat) of a long-acting insulin (Lente MC, Novo, Paris, France) 7 weeks after injection of streptozocin. The number of rats used was 17 for non diabetics, 14 for non-treated diabetics and 12 for diabetics treated with insulin. Animals were killed by exsanguination and blood was collected for serum glucose, insulin and hyaluronan determinations and further analysis when it was necessary. All experiments were conducted in accordance with institutional guidelines and recommendations for the care and use of laboratory animals established by French Ministry of Agriculture (autorization No. 002245). Serum hyaluronan was quantified with an Peripheral blood mononuclear cells from children with recent onset Type I diabetes (n = 10, black bars), first-degree relatives (FDRs, n = 3, white bars) and healthy control subjects (n = 7, hatched bars) were cultured for 1 week in serum-free HL/ 1 medium before measurement of H 3 -thymidine incorporation. Cultures contained the workshop antigens (doses are in mg/ml where indicated) and 10 U/ml IL2. GAD, glutamate decarboxylase 65 kD, GAD(PEVKEG), possible mimicry (GAD/Coxsackievirus) peptide, bacGAD, baculovirus-expressed GAD, coliGAD, GAD expressed in E. coli, pDR4, GAD peptides able to bind to DR4 heterodimers, HSP, heat shock protein peptide 277, INS-pept, overlapping insulin peptides. Insert: individual positive proliferative responses to any of the test antigens (U) and the % of test antigens that evoked positive responses are shown Corresponding author: Dr. A. Chajara, UniversitØ de MØde-cine-Pharmacie, Laboratoire DIFEMA-MERCI, 22, Boulevard Gambeta, 76 000 Rouen, France enzyme-linked sorbent assay using alkalin phosphatase conjugated sheep brain hyaluronectin. Phosphatase activity was measured by incubation with substrate (nitrophenyl phosphate). The Kruskal-Wallis test was used for multiple comparison followed by Mann-Whitney U test. Differences were regarded as significant at 2p less than 0.05.
Diabetic rats had hyperglycaemia, hypoinsulinemia and retarded body weight. These modifications were corrected by insulin (Table 1) . Diabetes induced a significant increase in serum hyaluronan concentration (2p < 0.00 001). This increase was also abolished by insulin treatment (Table 1) . Hyaluronan remained, however, higher than in non-diabetic rats (2p = 0.06). Since 90 % of circulating hyaluronan is taken up from blood by the liver, we verified whether the increased hyaluronan concentration in diabetic rats was a result of dysfunction of hyaluronan uptake from circulation. To respond to this question we determined serum alanine-aminotransferase in rats. We found that the activity of alanine-aminotransferase in serum of diabetics was about two times higher than that of non diabetics (2p < 0.00 001) and completely restored by insulin treatment ( Table 1) . As hyaluronidase, the enzyme which degrades hyaluronan, is also removed from circulation by liver, we wanted to know whether its activity in serum was also modified in diabetic rats. Serum hyaluronidase activity was determined by an indirect assay on plastic microtest plates coated with hyaluronan. Briefly, after incubation with samples and standard (human serum), wells were then incubated with hyaluronectin-phosphatase and phosphatase activity was determined using nitrophenyl phosphate. We observed that circulating hyaluronidase was also increased in diabetic rats (2p < 0.00001, Table 1 ). Hyaluronidase activity was restored by insulin treatment but remained significantly higher than in non diabetic rats (2p = 0.017).
Our data showed thus that circulating hyaluronan is increased in Type I diabetes. This finding could help to explain why hyaluronan accumulates in arteries of Type I diabetic patients. This could help furthermore to explain the mechanism of diabetic macroangiopathy, as there is little knowledge about the metabolic change in Type I diabetes responsible for the modifications of extracellular matrix components of the arterial wall. Hyaluronan, which forms a peri-cellular zone around arterial cells (endothelial and smooth muscle cells) is known, when it is present in increased amounts, to perturb arterial cell functions. Hyaluronan and hyaluronan-receptors, receptors for hyaluronan-mediated motility (RHAMM), and CD44 influence arterial smooth muscle cells migration and proliferation, both in vitro and in vivo [3, 4] . On the other hand, hyaluronan-oligosaccharides stimulate proliferation of endothelial cells in culture and high-molecular-mass hyaluronan inhibits formation and disturbs pre-existing endothelial cells monolayers [5] . Insulin treatment reduced, however, circulating hyaluronan but it did not completely abrogat its increase in diabetic rats. It is not, therefore, impossible that poorly controlled Type I diabetic patients have increased circulating hyaluronan. Alanine-aminotransferase has been found to be enhanced in Type I diabetic patients (treated with insulin) suggesting that insulin treatment did not prevent abnormal liver function in these patients [6] . On the other hand it has been reported that serum hyaluronan in diabetic patients (receiving insulin or other hypoglycaemic drugs) was significantly enhanced in comparison with non-diabetic subjects [7] .
Our study also showed that serum hyaluronidase was enhanced in Type I diabetic rats. Whether the increased concentration of this hydrolase in serum is associated with some damage in diabetes remains to be determined. Involvement of hyaluronidase, as well as hyaluronan, in physiopathological situations has, however, been intensively investigated in tumour development. Evidence was provided that both hyaluronidase and hyaluronan participate actively in tumour development as well as metastasis. It is of interest to note that diabetic patients have been found to be at excess risk of developing primary liver cancer [8] .
Yours sincerely, A. Chajara, M. Raoudi, B. Delpech, M. Leroy, J. P. Basuyau, H. Levesque Table 1 . Characteristics of rats during the experiment and at time of death. Body weight, serum glucose, insulin, alanine aminotransferase, hyaluronan and hyaluronidase
